Goldman Sachs Group Inc Bio N Tech Se Call Options Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

Call Options

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $2.76 Million - $4.39 Million	35,200 Added 208.28%	52,100 $6.19 Million
Q2 2024 Aug 13, 2024	BUY	$80.36 - $102.87 $409,836 - $524,637	5,100 Added 43.22%	16,900 $1.36 Million
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $1.05 Million - $1.33 Million	11,800 New	11,800 $1.09 Million
Q3 2023 May 14, 2024	BUY	$98.5 - $125.08 $1.52 Million - $1.93 Million	15,400 New	15,400 $1.67 Million
Q3 2023 Nov 14, 2023	BUY	$98.5 - $125.08 $1.52 Million - $1.93 Million	15,400 New	15,400 $1.67 Million
Q4 2022 May 14, 2024	BUY	$118.43 - $186.05 $5.28 Million - $8.3 Million	44,600 Added 65.88%	112,300 $16.9 Million
Q4 2022 Feb 13, 2023	BUY	$118.43 - $186.05 $5.28 Million - $8.3 Million	44,600 Added 65.88%	112,300 $16.9 Million
Q3 2022 May 14, 2024	BUY	$127.65 - $183.11 $4.81 Million - $6.9 Million	37,700 Added 125.67%	67,700 $9.13 Million
Q3 2022 Nov 10, 2022	BUY	$127.65 - $183.11 $4.81 Million - $6.9 Million	37,700 Added 125.67%	67,700 $9.13 Million
Q2 2022 May 14, 2024	BUY	$123.25 - $186.24 $3.7 Million - $5.59 Million	30,000 New	30,000 $4.47 Million
Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $5.52 Million - $8.34 Million	-44,800 Reduced 59.89%	30,000 $4.47 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $19.7 Million - $36.2 Million	-156,200 Reduced 67.62%	74,800 $12.8 Million
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $24 Million - $40.2 Million	111,000 Added 92.5%	231,000 $59.6 Million
Q3 2021 Nov 10, 2021	BUY	$205.93 - $447.23 $24.7 Million - $53.7 Million	120,000 New	120,000 $32.8 Million

Others Institutions Holding BNTX

# of Institutions

357

Shares Held

38.3M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account